Neumora Therapeutics Files 8-K
Ticker: NMRA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, corporate-update
TL;DR
Neumora filed an 8-K on Jan 13, 2025, with financial updates.
AI Summary
Neumora Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on financial statements and exhibits. The company, formerly known as RBNC Therapeutics, Inc., is incorporated in Delaware and headquartered in Watertown, MA.
Why It Matters
This filing provides official updates and disclosures from Neumora Therapeutics, Inc. to the SEC, which are important for investors to monitor company activities and financial status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- 001-41802 — SEC File Number (Identifies the company's filing with the SEC)
- 84-4367680 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- RBNC Therapeutics, Inc. (company) — Former company name
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Watertown, Massachusetts (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of January 13, 2025.
When was Neumora Therapeutics, Inc. formerly known as?
Neumora Therapeutics, Inc. was formerly known as RBNC Therapeutics, Inc., with a name change date of September 29, 2021.
In which state is Neumora Therapeutics, Inc. incorporated?
Neumora Therapeutics, Inc. is incorporated in Delaware.
What is the address of Neumora Therapeutics, Inc.'s principal executive offices?
The principal executive offices of Neumora Therapeutics, Inc. are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472.
What is the SEC file number for Neumora Therapeutics, Inc.?
The SEC file number for Neumora Therapeutics, Inc. is 001-41802.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-13 08:00:17
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq
Filing Documents
- d906757d8k.htm (8-K) — 25KB
- d906757dex991.htm (EX-99.1) — 43KB
- g906757ex99_1s10g1.jpg (GRAPHIC) — 87KB
- g906757ex99_1s11g1.jpg (GRAPHIC) — 75KB
- g906757ex99_1s12g1.jpg (GRAPHIC) — 61KB
- g906757ex99_1s13g1.jpg (GRAPHIC) — 66KB
- g906757ex99_1s14g1.jpg (GRAPHIC) — 66KB
- g906757ex99_1s15g1.jpg (GRAPHIC) — 93KB
- g906757ex99_1s16g1.jpg (GRAPHIC) — 131KB
- g906757ex99_1s17g1.jpg (GRAPHIC) — 113KB
- g906757ex99_1s18g1.jpg (GRAPHIC) — 87KB
- g906757ex99_1s19g1.jpg (GRAPHIC) — 93KB
- g906757ex99_1s1g1.jpg (GRAPHIC) — 30KB
- g906757ex99_1s20g1.jpg (GRAPHIC) — 132KB
- g906757ex99_1s21g1.jpg (GRAPHIC) — 70KB
- g906757ex99_1s22g1.jpg (GRAPHIC) — 100KB
- g906757ex99_1s23g1.jpg (GRAPHIC) — 97KB
- g906757ex99_1s24g1.jpg (GRAPHIC) — 126KB
- g906757ex99_1s25g1.jpg (GRAPHIC) — 82KB
- g906757ex99_1s26g1.jpg (GRAPHIC) — 34KB
- g906757ex99_1s27g1.jpg (GRAPHIC) — 87KB
- g906757ex99_1s28g1.jpg (GRAPHIC) — 111KB
- g906757ex99_1s29g1.jpg (GRAPHIC) — 86KB
- g906757ex99_1s2g1.jpg (GRAPHIC) — 184KB
- g906757ex99_1s30g1.jpg (GRAPHIC) — 92KB
- g906757ex99_1s31g1.jpg (GRAPHIC) — 74KB
- g906757ex99_1s32g1.jpg (GRAPHIC) — 66KB
- g906757ex99_1s3g1.jpg (GRAPHIC) — 98KB
- g906757ex99_1s4g1.jpg (GRAPHIC) — 82KB
- g906757ex99_1s5g1.jpg (GRAPHIC) — 89KB
- g906757ex99_1s6g1.jpg (GRAPHIC) — 98KB
- g906757ex99_1s7g1.jpg (GRAPHIC) — 77KB
- g906757ex99_1s8g1.jpg (GRAPHIC) — 90KB
- g906757ex99_1s9g1.jpg (GRAPHIC) — 94KB
- 0001193125-25-004999.txt ( ) — 4161KB
- nmra-20250113.xsd (EX-101.SCH) — 3KB
- nmra-20250113_lab.xml (EX-101.LAB) — 18KB
- nmra-20250113_pre.xml (EX-101.PRE) — 11KB
- d906757d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Corporate Presentation dated January 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Joshua Pinto Joshua Pinto Chief Financial Officer